ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

恩扎鲁胺 医学 前列腺癌 多西紫杉醇 雄激素剥夺疗法 内科学 安慰剂 肿瘤科 临床终点 泌尿科 危险系数 癌症 随机对照试验 雄激素受体 病理 置信区间 替代医学
作者
Andrew J. Armstrong,Russell Zelig Szmulewitz,Daniel Peter Petrylak,Jeffrey M. Holzbeierlein,Arnauld A. Villers,Arun Azad,Antonio Alcaraz,B. Yа. Alekseev,Taro Iguchi,Neal D. Shore,Brad Rosbrook,Jennifer E. Sugg,Benoît Baron,Lucy L Chen,Arnulf Stenzl
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (32): 2974-2986 被引量:1339
标识
DOI:10.1200/jco.19.00799
摘要

PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). METHODS ARCHES (ClinicalTrials.gov identifier: NCT02677896 ) is a multinational, double-blind, phase III trial, wherein 1,150 men with mHSPC were randomly assigned 1:1 to enzalutamide (160 mg/day) or placebo, plus androgen deprivation therapy (ADT), stratified by disease volume and prior docetaxel chemotherapy. The primary end point was radiographic progression-free survival. RESULTS As of October 14, 2018, the risk of radiographic progression or death was significantly reduced with enzalutamide plus ADT versus placebo plus ADT (hazard ratio, 0.39; 95% CI, 0.30 to 0.50; P < .001; median not reached v 19.0 months). Similar significant improvements in radiographic progression-free survival were reported in prespecified subgroups on the basis of disease volume and prior docetaxel therapy. Enzalutamide plus ADT significantly reduced the risk of prostate-specific antigen progression, initiation of new antineoplastic therapy, first symptomatic skeletal event, castration resistance, and reduced risk of pain progression. More men achieved an undetectable prostate-specific antigen level and/or an objective response with enzalutamide plus ADT ( P < .001). Patients in both treatment groups reported a high baseline level of quality of life, which was maintained over time. Grade 3 or greater adverse events were reported in 24.3% of patients who received enzalutamide plus ADT versus 25.6% of patients who received placebo plus ADT, with no unexpected adverse events. CONCLUSION Enzalutamide with ADT significantly reduced the risk of metastatic progression or death over time versus placebo plus ADT in men with mHSPC, including those with low-volume disease and/or prior docetaxel, with a safety analysis that seems consistent with the safety profile of enzalutamide in previous clinical trials in castration-resistant prostate cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
科目三的应助被sooooly采纳,获得10
1秒前
科目三的应助被张文凯采纳,获得10
1秒前
zws完成签到,获得积分10
1秒前
Downey完成签到,获得积分10
1秒前
栗子卷发布了新的文献求助10
1秒前
syvshc的应助被PbIr采纳,获得10
1秒前
2秒前
Hello的应助被vv采纳,获得10
3秒前
无花果的应助被酷酷柚子采纳,获得10
3秒前
迅速孱发布了新的文献求助10
3秒前
4秒前
4秒前
4秒前
所所的应助被永昼采纳,获得10
5秒前
懒洋洋完成签到,获得积分10
5秒前
7秒前
zrkkk完成签到,获得积分10
7秒前
Orange的应助被czj采纳,获得10
7秒前
香蕉觅云的应助被回顾及采纳,获得10
7秒前
7秒前
8秒前
害羞大雁完成签到,获得积分10
8秒前
9秒前
山风完成签到,获得积分10
9秒前
今后的应助被柒柒柒采纳,获得10
9秒前
9秒前
Peetvader发布了新的文献求助10
10秒前
vivi完成签到,获得积分10
10秒前
三只熊发布了新的文献求助10
10秒前
10秒前
10秒前
哈哈哈发布了新的文献求助10
10秒前
钱旭枫完成签到,获得积分20
10秒前
Seven发布了新的文献求助10
11秒前
霍师傅发布了新的文献求助10
11秒前
MMM发布了新的文献求助10
11秒前
可爱的函函的应助被酷酷柚子采纳,获得10
11秒前
12秒前
2025210129发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178280
求助须知:如何正确求助?哪些是违规求助? 9569046
关于积分的说明 21802436
捐赠科研通 7773138
什么是DOI,文献DOI怎么找? 3432735
关于科研通互助平台的介绍 2556770
邀请新用户注册赠送积分活动 2478274